Despite its rarity (1%-2%), acute graft-versus-host disease after liver transplantation (LT-aGVHD) has a high mortality rate (85%). A gradual decrease in regulatory T cells (Tregs) correlates with disease progression in a rat LT-GVHD model, and treatments which increase Tregs exert therapeutic effects on LT-aGVHD. In this study, LT-aGVHD model rats were treated with rapamycin (RAPA), OSI-027, or an equal quantity of vehicle. Rats treated with OSI-027 survived longer (>100 days) than those in the RAPA (70 6 8 days) or control (24 6 3 days) groups. Flow cytometric analysis showed that the Treg ratios in peripheral blood mononuclear cells in the OSI-027 group were higher than those in the RAPA or control groups. The proportions of donor-derived lymphocytes in the OSI-027 group were lower than those in the RAPA or control groups. Hematoxylin-eosin staining of skin tissue demonstrated less severe lymphocyte infiltration in the OSI-027 group than that in the RAPA or control groups. In vitro, OSI-027 induced differentiation of CD4 1 CD25 -T cells into CD4 
Despite its rarity (1%-2%), acute graft-versus-host disease after liver transplantation (LT-aGVHD) has a high mortality rate (85%). A gradual decrease in regulatory T cells (Tregs) correlates with disease progression in a rat LT-GVHD model, and treatments which increase Tregs exert therapeutic effects on LT-aGVHD. In this study, LT-aGVHD model rats were treated with rapamycin (RAPA), OSI-027, or an equal quantity of vehicle. Rats treated with OSI-027 survived longer (>100 days) than those in the RAPA (70 6 8 days) or control (24 6 3 days) groups. Flow cytometric analysis showed that the Treg ratios in peripheral blood mononuclear cells in the OSI-027 group were higher than those in the RAPA or control groups. The proportions of donor-derived lymphocytes in the OSI-027 group were lower than those in the RAPA or control groups. Hematoxylin-eosin staining of skin tissue demonstrated less severe lymphocyte infiltration in the OSI-027 group than that in the RAPA or control groups. In vitro, OSI-027 induced differentiation of CD4 1 CD25 -T cells into CD4 Although acute graft-versus-host disease (aGVHD) is an uncommon (1%-2%) complication of liver transplantation (LT), (1) the high mortality (85%-90%) poses a major therapeutic challenge. ( 2) The precise mechanisms of acute graft-versus-host disease after liver transplantation (LT-aGVHD) remain to be elucidated, and the current methods for prevention or therapy are controversial. At present, treatments for LT-aGVHD include increasing or withdrawing immunosuppression, which are controversial and ineffective in many situations (3) (4) (5) (6) ; therefore, the identification of effective treatments for LT-aGVHD are urgently needed.
To overcome the challenge in detecting the mechanisms of LT-aGVHD arising from the low incidence of this complication, we developed a rat model of LTaGVHD and showed that the relative decrease in the proportion of regulatory T cells (Tregs) in the peripheral blood mononuclear cells (PBMCs) is associated with disease progression. (7, 8) Tregs play an important role in maintaining self-tolerance and immune tolerance after allogeneic transplantation. (9) (10) (11) Recently, a number of studies have shown that increasing the ratio of Tregs can suppress aGVHD after bone marrow transplantation (BMT). (12) (13) (14) Our previous studies also showed that rapamycin (RAPA) and mesenchymal stem cells increase the percentage of Tregs in the PBMCs and improve the survival rate in a rat model. (15, 16) OSI-027 is an orally bioavailable RAPA analogue, which is in phase 2 clinical trials as an antitumor drug. However, unlike RAPA, which inhibits only protein synthesis associated with the mammalian target of rapamycin complex 1 (mTORC1), (17) (18) (19) OSI-027 also inhibits mammalian target of rapamycin complex 2 (mTORC2), which regulates the cytoskeleton. (17) (18) (19) OSI-027 has shown greater efficacy than RAPA in the suppression of growth in a variety of tumor types, (20, 21) although its role in GVHD remains to be determined. Thus, in this study, we compared the effects of OSI-027 and RAPA as immune inhibitors in the treatment of LT-aGVHD in a rat model.
Materials and Methods

ANIMALS
Specific pathogen-free female Lewis rats (Beijing Vital River, Beijing, China), male BN rats (Beijing Vital River), and male green fluorescent protein-transgenic lewis rat (Lew-Tg [CAG-EGFP] YsRrrc) rats (Rat Resource and Research Center, University of Missouri, Columbia, MO) were housed under specific pathogenfree conditions. Male Lew-TgYsRrrc rats were donors in the liver transplantation, and male F1 (Lewis#*BN$) rats were recipients. All experiments were conducted in accordance with the guidelines of the Animal Ethics Committee of Zhejiang University.
RAT MODEL OF LT-aGVHD AND EXPERIMENTAL GROUPS
LT-aGVHD model rats were generated as described previously. (7) Briefly, orthotopic LT was undertaken according to the technique described by Kamada and Calne without anastomosis of the hepatic artery. No antibiotics were used. Freshly prepared splenocytes (4 3 10 8 , suspended in 500 mL phosphate-buffered saline [PBS]) of Lew-Tg YsRrrc rats were infused into each recipient via the dorsal penile vein immediately after LT (within 30 minutes). LT-aGVHD model rats were divided into 3 experimental groups: RAPA (1 mg/kg), OSI-027 (1 mg/kg), or control (equal quantity of vehicle) groups. Treatments were administered via the vena caudalis from day 7 to day 15.
ASSESSMENT OF LT-aGVHD
The typical signs of LT-aGVHD, such as diarrhea, dermatitis, alopecia, weight loss, hunched posture, and cachexia were assessed every 2 days. The mean survival time and the survival rate of each group were calculated at the end of the 100-day observation period.
Five model rats from each group were killed by cervical dislocation on day 15 after LT, and the samples (skin, intestine, and liver) were placed in buffered neutral formalin before embedding in paraffin. Sections (3-lm thick) were then prepared and stained with hematoxylineosin (H & E). Slides were randomly coded without reference to experimental groups, and a pathologist who was blind to the code was invited to note the microscopic abnormalities typically associated with LT-aGVHD.
Blood (1 mL) from each model rat was sampled from the vena caudalis 12 days after LT, and the serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor a (TNF-a), and interferon c (IFNc) and interleukin 2 (IL2) levels were measured with standard techniques.
FLOW CYTOMETRIC ANALYSIS
Blood samples (1 mL) were obtained from model rats via the vena caudalis on days 5, 10, and 15 after LT. Red blood cells (RBCs) were lysed using the RBC Lysis Buffer (BioLegend, San Diego, CA), and the lymphocytes were isolated using Lymphocyte Separation Medium (Haoyang, Tianjin, China). The lymphocytes were incubated with anti-rat CD4/antigen presenting cell (APC) antibody (BioLegend, San Diego, CA) and antirat CD25/phycoerythrin (PE) antibody (BioLegend) for 30 minutes at 4 8C. The cells were then fixed with a fixation/permeabilization buffer (eBioscience, San Diego, CA) for 45 minutes at room temperature, followed by permeabilization with permeabilization buffer (eBioscience, San Diego, CA) and incubation with anti-rat forkhead box P3 (FOXP3)/PE-Cy5 antibody (BioLegend) according to the manufacturer's instructions. The proportion of CD4
FOXP3
1 Treg cells was determined by flow cytometric analysis (Cytomics FC500, Beckman Coulter, Brea, CA).
WESTERN BLOT ANALYSIS
Lymphocytes were isolated from the PBMCs of model rats (day 15) as described previously. Samples of cell lysate proteins (40 mg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The membranes were blocked with Tris-buffered saline/0.1% Tween 20 containing 5% bovine serum albumin and incubated with specific primary antibodies (all 1:1000 dilution) for 6 hours. 
FLOW CYTOMETRIC AND MAGNETIC SORTING OF CELLS
Lymphocytes were obtained from PBMCs or spleens of model rats as described previously. The green fluorescent protein (GFP) 1 and GFP -lymphocytes isolated from PBMC were separated using flow cytometry; whereas the CD4 1 and CD25 1 lymphocytes isolated from the spleen of model rats were isolated using magnetic sorting according to the manufacturer's instruction (Miltenyi Biotec, Teterow, Germany).
IMMUNOHISTOCHEMICAL ANALYSIS
Skin and intestine samples obtained from model rats were fixed in formalin and embedded in paraffin as described previously before sections (3-lm thick) were prepared. For immunohistochemical staining, the sections were incubated with anti-GFP antibody (1:500) in accordance with the manufacturer's protocol, and then with HRP-conjugated antibodies against rabbit immunoglobulin using HistostainPlus Kit (Haoran-Bio, Shanghai, China). Sections were then counterstained with H & E. The specific primary antibody was replaced with PBS in the negative controls.
mTORC2 KNOCKDOWN BY SMALL INTERFERING RNA
Expression of mTORC2 was knocked down using small interfering RNA (siRNA) technology (GenePharma, Shanghai, China). The mTORC2 siRNA or negative-control siRNA (100 nM) was transfected into CD4 1 CD25 -lymphocytes using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as the transfection carrier according to the manufacturer's instruction. The efficiency of siRNA interference was assessed by Western blot analysis.
1-WAY MIXED LYMPHOCYTE CULTURE
F1 and Lewis rats were killed by cervical dislocation. The spleens were removed and strained through metal cell sieves, and the cell suspensions centrifuged at 2000 rpm/minutes for 5 minutes. The supernatant was aspirated completely, and RBCs were lysed using RBC Lysis Buffer (BioLegend). The cells were centrifuged again and resuspended in Roswell Park Memorial Institute 1640 medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO). F1 lymphocytes were treated overnight with mitomycin C (1 mg/L; Sigma-Aldrich) and then mixed with Lewis lymphocytes to establish the in vitro 1-way mixed lymphocyte culture (MLC) model. To detect the effects of RAPA and OSI-027 on the proportion of Tregs, the MLC cells were plated at a density of 100,000 per well in 6-well plates in medium containing RAPA (100 nM) or OSI-027 (100 nM). After 4 days, the cells were harvested and isolated using lymphocyte separation medium before staining with anti-rat CD4/APC antibody, anti-rat CD25/ PE antibody, and anti-FOXP3 antibody as described previously. The proportion of CD4 
FOXP3
1 Treg cells were determined by flow cytometry.
CD4
CD25 -T CELL DIFFERENTIATION IN VITRO
The F1 and Lewis 1-way MLC was established, and the spleen cells of Lew-Tg (CAG-EGFP) YsRrrc rats were acquired as described previously. Spleen cells were stained with anti-rat CD4/APC antibody and anti-rat CD25/ PE antibody. The CD4 1
CD25
-T cells were harvested by flow cytometric sorting, mixed with the MLC cells and divided into 3 groups that were then treated with RAPA (100 nM), OSI-027 (100 nM), or an equal quantity of vehicle. After 4 days, the cells were harvested and stained with anti-rat CD4/APC antibody, anti-rat CD25/PE antibody, and anti-rat FOXP3/PE-Cy5 antibody as described previously. The proportion of
T cells was determined by flow cytometry.
THE EFFECTS OF TREGS ON THE LT-aGVHD
The F1 and Lewis spleen cell 1-way MLC was established as previously described, and the cells were treated with OSI-027 for 4 days. The
1 Treg cells were then harvested by magnetic sorting as described previously. Eight LT-aGVHD model rats were established and divided into 2 groups treated with Treg (4 3 10 8 /per model rat) or the vehicle on the second day after surgery. The proportions of Tregs and donor-derived mononuclear cells in the PBMCs were detected on days 4 and day 12 using flow cytometry analysis. The samples of skin and liver were acquired at the time of death or 30 days after surgery.
STATISTICAL ANALYSIS
Data were analyzed with SPSS 15.0 for Windows (IBM, Armonk, NY). A Kaplan-Meier survival analysis was performed, and differences between survival curves were estimated with the log-rank test. A 1-way analysis of variance was used to compare group variables, followed by least significant difference post hoc testing when it was indicated. Values were expressed as means and standard deviations. P < 0.05 was considered to indicate statistical significance.
Results
THE EFFECTS OF RAPA AND OSI-027 ON LT-aGVHD
All model rats in the control group developed typical LTaGVHD symptoms as described in our previous reports (8) and died 17-26 days after LT. In the RAPA group, 3 rats exhibited symptoms typical of LT-aGVHD and died 27 to 35 days after LT; the remaining 5 rats did not develop LTaGVHD symptoms and survived for more than 100 days. In contrast, 7 rats in the OSI-027 group survived for more than 100 days without symptoms of LT-aGVHD, and only 1 rat exhibited LT-aGVHD symptoms and died on day 33 after LT (Fig. 1A) .
The average weight loss among the model rats in the RAPA group was slightly greater than that in the control group, whereas the average weight of the OSI-027 group remained stable (Fig. 1B) . The model rats in the OSI-027 group also appeared healthier than those in the RAPA or control groups (Fig. 1C) .
The histological examination of skin samples showed typical pathological features of aGVHD in the control group but not in those in the RAPA and OSI-027 groups. The liver grafts in the model rats in all 3 groups were normal without obvious mononuclear infiltrates within the portal tracts or sinusoids (Fig. 1D) .
THE EFFECTS OF RAPA AND OSI-027 ON CD4
1 CD25 1
FOXP3
TREG CELLS
Flow cytometric analysis showed that in the control group the proportion of Treg among the model rat PBMCs decreased from 7.9% 6 1% (day 4) to 2.4% 6 0.4% (day 12), whereas the proportion remained stable in the RAPA group (7.9% 6 1%, day 4; 8.8% 6 0.9%, day 12). However, the proportions of Tregs among the PBMCs in the OSI-027 group increased from 7.8% 6 1% (day 4) to 14.3% 6 1.2% (day 12; Fig. 2A ). These trends in the MLC were consistent with those identified in vivo (from 6.2% 6 0.9% to 2.5% 6 0.3% in the control group; from 6.5% 6 0.8% to 6.9% 6 0.7% in the RAPA group; and from 6.3% 6 0.8% to 13.1% 6 1.2% in the OSI-027 group; Fig. 2B ).
THE EFFECTS OF RAPA AND OSI-027 ON DONOR-DERIVED CELLS
The proportions of donor-derived GFP 1 cells in model rat PBMCs were increased from 15.3% 6 1.6% (day 4) to 74.8% 6 5.3% (day 12) in the control group and from 13.9% 6 1.8% (day 4) to 33.7% 6 2.6% (day 12) in the RAPA group. However, the increase in the proportion of donor-derived GFP 1 cells in the OSI-027 group, from 15.1% 6 1.7% (day 4) to 22.5% 6 2.3% (day 12), was smaller than those in the RAPA and control groups (Fig. 3A) .
Immunohistochemical analysis showed that the average amount of donor-derived cells in the control group was 79 in the skin and 432 in the intestine. In RAPA and OSI-027 groups, the average amount of donor-derived cells in the skin was 22 and 8, respectively, and in the intestine, the average amount of donor-derived cells was 212 and 98, respectively. The amount of donor-derived GFP 1 cells in the F1 control group (without liver and cell tranplantation) was 0 (Fig. 3B) . The proportions of donor-derived GFP 1 Treg among the total Tregs were 9.4% (day 5) and 6.5% (day 15) in the control group, and 7.5% (day 5) and 34.5% (day 15) in the RAPA group, whereas in the OSI-027 , and OSI-027 (n 5 8) groups. Both RAPA and OSI-027 increased the survival rate of LT-aGVHD model rats (P < 0.001), although OSI-027 was more effective than RAPA in decreasing the mortality rate (P 5 0.01). (B) OSI-027 was more effective than RAPA in reducing weight loss in model rats (P 5 0.02). (C) The health status of model rats in the RAPA group was better than that in the control group, but worse than that in the OSI-027 group. (D) Representative skin and liver biopsy samples obtained on day 12 after LT. H & E staining showed that levels of mononuclear cell infiltration in skin tissues in RAPA and OSI-027 groups were lower than the control group (n 5 5 per group; P < 0.001). There was also no obvious mononuclear infiltration within the portal tracts or sinusoids of the liver grafts in the 3 groups (P 5 0.2).
FIG. 2. The effects of RAPA and OSI-027 on Tregs in vivo and in vitro. (A) Flow cytometric analysis
showing the changes in the ratio of Tregs in the PBMCs of model rats. The proportion of Tregs decreased progressively in the control group (n 5 8) but remained stable in the RAPA group (n 5 8 per group; P < 0.001). The ratio of Tregs in the OSI-027-treated group (n 5 8) increased to levels higher than those in the RAPA and control groups (P < 0.001). (B) In vitro MLCs confirmed that the changes in the ratios of Tregs in these groups were consistent with those observed in vivo. The proportions changed from 6.2% (day 2) to 2.5% (day 5) in the control group (n 5 5), from 6.5% (day 2) to 6.9% (day 5) in the RAPA group (n 5 5; P < 0.001), and from 6.3% to 13.4% in the OSI-027 group (n 5 5; P < 0.001).
FIG. 3. The effects of RAPA and OSI-027 on donor-derived mononuclear cells. (A)
Flow cytometric analysis demonstrated marked increases in the proportion of donor-derived mononuclear cells in the PBMCs of model rats in the control group; this effect was inhibited by RAPA treatment (P < 0.001) and OSI-027, with a more potent effect mediated by OSI-027 (P < 0.001). (B) Representative skin and intestine biopsy samples were obtained 12 days after LT. Immunohistochemical staining showed significant infiltrations of the skin and intestine tissues by donor-derived mononuclear cells in the control group, whereas both RAPA and OSI-027 significantly reduced infiltration (P < 0.001), with a more potent effect mediated by OSI-027 (P < 0.001). No GFP+ cell was found in the skin and intestine tissues in the F1 control group. group, the proportions of GFP 1 Tregs increased from 9.8% (day 5) to 66.4% (day 15; Fig. 4A ).
CHANGES IN MAMMALIAN TARGET OF RAPAMYCIN EXPRESSION
The donor-derived GFP 1 cells and recipient-derived GFP -cells were isolated from the PBMCs of model rats at day 15 (Fig. 4B) . Western blot analyses showed that there were no differences in the expression of mTOR pathway effectors between the donor-derived GFP 1 cells and the Lewis rat PBMCs. However, the expression of mTOR (ser2481), mammalian target of rapamycin (mTOR) (2448), Phospho-Akt (p-Akt,) Phospho-4E-BP-1 (p-4E-BP-1), and phospho-p70S6K (p-p70S6K) in donorderived GFP 1 cells was higher than that in F1 rat PBMCs (Fig. 4C) .
OSI-027 significantly inhibited the expression of mTOR pathway effectors, including mTOR (ser2481), mTOR (ser2448), Phospho-Akt (p-Akt), Phospho-4E-BP-1 (p-4E-BP-1), and p-p70S6K in model rat PBMCs. However, RAPA inhibited only mTOR (2481) and p70S6K phosphorylation, with no significant effects on mTOR (ser2448), Akt, and 4E-BP-1 phosphorylation (Fig. 4D) .
The biochemical analysis showed that both RAPA and OSI-027 could decrease the level of inflammatory cytokines, such as TNF-a, IFNc, and IL2 (Supporting Fig.  1A) . The AST and ALT levels between these groups have no difference (Supporting Fig. 1B) .
THE EFFECTS OF RAPA AND OSI-
027 ON CD4 1 CD25 -CELLS CD4 1
CD25
-lymphocytes were obtained from LTaGVHD model rats by flow cytometric sorting (Fig. 5A) . Rictor (mTORC2) expression in CD4 
-lymphocytes was successfully knocked down by Rictor siRNA (Fig.  5B ). In the in vitro MLC model, CD4
1 CD25 -lymphocytes were treated with vehicle, RAPA, or OSI-027, and the mTORC2 knocked down CD4 
-lymphocytes were treated with RAPA. After 5 days, 6% 6 1.2% of GFP 1 T cells were found to be CD4
lymphocytes in the OSI-027 group. The proportion in the RAPA group and the control group was 0.2% 6 0.1% and 0.9% 6 0.1%, respectively. However, after treatment of Rictor knocked down CD4 
FOXP3
1 T cells reached 4.7% 6 0.9%, which was much higher than the proportion in the group treated with RAPA alone (Fig. 5C) .
THE EFFECT OF CD24
1 CD25 1 FOXP3 1 TREGS ON LT-aGVHD CD24 1 CD25 1
FOXP3
1 Tregs induced by OSI-027 in vitro and acquired by magnetic sorting were injected into the peripheral blood of the model rats via the vena caudalis. All model rats in the control group died between 17 and 24 days after LT. In the Treg-treated group, 4 model rats survived for more than 40 days, and 1 died of LT-aGVHD at 27 days after surgery (Fig. 6A) . The model rats in the Tregtreated group were healthier than those in the control group in terms of weight loss and appearance (Fig. 6B,C, respectively) . Histological examination of skin samples showed typical pathological features of aGVHD in the control group but not in the Treg-treated group (Fig. 6D) . Flow cytometric analysis showed that the proportion of Treg in the control group decreased from 5.8% 6 1% (day 8) to 2.9% 6 0.4% (day 12). In the Treg group, the proportion of Tregs also decreased from 13.2% 6 2.6% to 9.2% 6 1.5% (Fig. 6E) . The proportion of donor-derived cells in the control group increased from 17.3% 6 3.6% (day 8) to 71.1% 6 6.9% (day 12), which was greater than the increase observed in the Treg-treated group from 9.2% 6 1.3% (day 8) to 22.1% 6 3.5% (day 12; Fig. 6F ).
Discussion
The etiology and pathophysiology of LT-aGVHD remain uncertain, and effective treatments are lacking. In this study, we used a previously established rat model of LT-aGVHD to show that the occurrence and progression of this disease is associated with decreased numbers of Tregs in model rat PBMCs. (7, 8) Tregs are a subset of CD4 1 T cells distinguished by from other T cell populations by unique expression of FOXP3. Tregs are designated thymus-derived regulatory T cells, peripherally derived regulatory T cells (pTregs), and in vitro-derived regulatory T cells (iTregs), according to the locations in which they were generated. Furthermore, these subsets express common surface receptors that are associated with their functions, including cytotoxic T lymphocyte antigen 4, glucocorticoid induced tumor necrosis factor receptor (GITR), CD103, and ICOS, Inducible T cell COStimulator; ICOS. (22) Tregs have potent immunomodulatory activity and play an important role in maintaining self-tolerance by preventing the activation of dendritic cells, (23, 24) suppressing established CD4
1
T cell-mediated inflammation, (25, 26) and further T cell proliferation and activation. (27, 28) They are also crucial in the induction of tolerance after solid organ transplantation. (9) (10) (11) Recently, it has been shown that Tregs inhibit GVHD in models of BMT. (12) (13) (14) Our previous research also showed that RAPA increases the proportion of Tregs among PBMCs and reduces the mortality rate in a rat model of LT-aGVHD. (15) In this study, we treated the LT-aGVHD model rats with the mTOR inhibitor RAPA and its analogue OSI-027. Although RAPA reduced the mortality rate of LT-aGVHD model rats, a higher survival rate was observed in the OSI-027 group. Equally, the degree of donor-derived mononuclear cell infiltration in the RAPA group was obviously lower than that in the control group but was still higher than that in the OSI-027 group. Flow cytometric analysis showed a significant decrease in the ratio of Tregs in the control group, whereas the ratio in the RAPA group remained stable. In contrast, the proportion of Tregs among the PBMCs in the OSI-027-treated model rats increased H & E staining of the skin tissues showed that in the control group, the epidermis and dermis were infiltrated by numerous mononuclear cells. In contrast, in the Treg group, there was no obvious mononuclear cell infiltration in the skin tissue (P < 0.001). (E) Flow cytometric analysis showed the ratio of Tregs in the Tregs group was higher than that in the control group (n 5 5 per group; P < 0.001). (F) The proportion of donor-derived mononuclear cells in the control group was higher than that in the Treg group (P < 0.001).
markedly. Furthermore, OSI-027 was more potent than RAPA in suppressing the proliferation of donorderived mononuclear cells. These results were in accordance with our previous findings. (15, 16) Altman et al. found that OSI-027 can inhibit the proliferation of bone marrow-derived cells, including Tregs. (17) In our research, we found that increased Tregs ratio was not due to the proliferation of Tregs from bone marrow; OSI-027 inhibited mTORC1/mTORC2 and induced the donor-derived T cells that differentiated into Tregs.
The mTOR pathway plays a crucial role in the regulation of T cell activation, differentiation, and function. The mTOR-deficient T cells proliferate slowly when activated and fail to differentiate into T helper (T h ) 1, T h 2, and T h 17 subsets under appropriate skewing conditions. (29) Recent studies demonstrated that mTOR can be activated by the T cell receptor, costimulatory signals, and various cytokines. (30) In accordance with these findings, the results of this study showed that the expression of mTORC1 and mTORC2 in model rat donor-derived mononuclear cells was higher than that in normal Lewis rat PBMCs. Several studies have demonstrated that mTOR deficiency disables effector lineage differentiation and diverts CD4
1 T cells into iTregs, even in the absence of exogenous Treg-polarizing cytokines. (23, 29, 31) Furthermore, RAPA induced the stimulated CD4
1 T cells to differentiate into Tregs. In the present study, 66.4% of the Tregs among the PBMC in OSI-027-treated model rats were donor derived, whereas in the RAPA-treated and control groups, the proportions were 34.5% and 6.5%, respectively. In vitro MLCs showed that OSI-027 was more potent than RAPA in promoting the differentiation of CD4 1
CD25
-T cells into CD4 
-T cells achieved the same effects as OSI-027. Western blot analysis showed that both RAPA and OSI-027 inhibited mTORC1, whereas OSI-027 inhibited mTORC2 more rapidly and effectively than RAPA. mTOR deficiency resulted in marked differentiation of CD4 1 T cells into Tregs, although abrogation of both mTORC1 and mTORC2 was required. (32) In CD4 1 T cells, mTORC2 is insensitive to RAPA in short-term or low-dose treatment but can be blocked by longterm or high-dose RAPA treatment. (29, 33) In the present study, we used a low dose of RAPA (1 mg/kg) to prevent death of the model rats due to infection. As a result, inhibition of mTORC2 in the PBMCs of model rats was not achieved at this dose of RAPA and the effect in inducing Tregs was inferior to that of OSI-027. Finally, we used OSI-027 to induce pTregs in vitro, which were then injected into the peripheral blood of the model rats. These pTregs suppressed proliferation of donor-derived PBMCs and prevented LT-aGVHD.
In this study, we used Lew-Tg (CAG-EGFP) YsRrrc rats as donors for a model of LT-aGVHD, and we demonstrated the relationship between disease progression and changes in the donor-derived population of mononuclear cells. OSI-027, a 2-pronged mTOR inhibitor, promoted the differentiation of CD4 1 T cells into Tregs and suppressed the proliferation of donor-derived mononuclear cells, in addition to reducing the secretion of inflammatory cytokines. Consequently, OSI-027 reduced the damage to the tissues and organs of the recipients and improved the survival rate of the LT-aGVHD model rats. This demonstration of the effective use of OSI-027 to treat LTaGVHD in a rat model indicates the potential of this antitumor drug in the clinical treatment of LTaGVHD or other diseases of the immune system.
